Nobuhiko Tamura is Sunovion's champion of drug discovery and development and primary architect of the R&D that fuels the company’s dynamic discovery and development efforts.
He was appointed President in November 2014, after assuming the executive leadership role as Sunovion Vice Chair, Board of Directors in April 2014. Mr. Tamura also serves as a Senior Executive Officer of Sumitomo Dainippon Pharma Co., Ltd. Group, the parent company of Sunovion.
Previously, as Chief Scientific Officer of Sunovion, Mr. Tamura led the submission to the FDA of Latuda (lurasidone HCl), an atypical antipsychotic approved in 2010 for the treatment of schizophrenia in adults. He was the President of Dainippon Sumitomo Pharma America (DSPA) prior to the acquisition of Sepracor Inc.
Mr. Tamura began his career as a researcher at Sumitomo Chemical Co., Ltd. and was one of the first employees of Sumitomo Pharmaceutical Co., Ltd. (SP), which was created in 1984. After six years in SP's discovery lab, he worked in the business development group in New York and served as the company’s US representative. From 1994 to 2007, he led multiple chemical and biological projects in the R&D Division of SP and Sumitomo Dainippon Pharma, and fostered the development of new chemical entities for the treatment of central nervous system diseases and other disorders.
Mr. Tamura serves on the Board of Directors of the Pharmaceutical Research & Manufacturers of America (PhRMA).
Mr. Tamura earned his master’s degree in pharmacy from Tohoku University and his bachelor’s degree in pharmacy from the Tokyo University of Science.